Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642 | 0.83 | POLB (0.52) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL1449785 | 0.83 | MEN1 (0.52) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL18031697 | 0.82 | L3MBTL1 (0.53) | KMT2AMEN1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL29142060 | 0.82 | MEN1 (0.58) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL7960432 | 0.81 | L3MBTL1 (0.53) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL17321305 | 0.80 | ALDH1A1 (0.50) | KMT2AMEN1L3MBTL1EGFRERBB2 | |
| SCHEMBL2208662 | 0.80 | GAA (0.52) | KMT2AMEN1KDM4EEGFRERBB2 | |
| SCHEMBL1535041 | 0.79 | CES1 (0.54) | KMT2AMEN1L3MBTL1KDM4EHPGD | |
| Ethylene SCHEMBL10772569 | 0.79 | POLB (0.48) | KMT2AMEN1L3MBTL1KDM4EGLA | |
| SCHEMBL3868190 | 0.79 | KMT2A (0.49) | KMT2AMEN1L3MBTL1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | KMT2A 1299/4885MEN1 633/4885L3MBTL1 3300/4885 |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | KMT2A 2422/4885MEN1 994/4885L3MBTL1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.